NASDAQ:SYBX

Synlogic Q3 2026 Earnings Results & Report

Synlogic logo
$0.98 0.00 (0.00%)
As of 11/18/2026 11:03 AM Eastern

Synlogic beat analyst earnings expectations in its Q3 2026 results, released November 10, 2026. The company reported EPS of -$0.31 versus the -$5.80 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Synlogic EPS Results

Actual EPS
-$0.31
Consensus EPS
-$5.80
Beat/Miss
Beat by +$5.49
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Synlogic Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Synlogic Q3 2026 Earnings FAQ

Synlogic (NASDAQ:SYBX) reported earnings of -$0.31 per share for Q3 2026, beating the consensus estimate of -$5.80. The report was announced on Tuesday, November 10, 2026.

Synlogic Earnings Headlines

Synlogic (SYBX) Set to Post Earnings on Wednesday
Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
Synlogic Challenges Nasdaq Delisting Notice
See More Synlogic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synlogic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synlogic and other key companies, straight to your email.

About Synlogic

Synlogic (NASDAQ:SYBX) is a biotechnology company that has focused on developing “synthetic biotics”—engineered bacteria designed to perform therapeutic functions in the body. Its approach uses synthetic biology to modify microbes so they can produce or consume specific substances, with the aim of treating disease.

The company’s research has centered on rare metabolic disorders, including phenylketonuria (PKU) and homocystinuria. Its investigational programs were designed to help break down compounds that build up in people with these conditions. Synlogic has not been known for marketed medicines; its work has been primarily in research and clinical development.

Founded in 2013 as a spinout from the Massachusetts Institute of Technology, Synlogic has been based in Cambridge, Massachusetts. Its programs and platform have been directed mainly toward the development of treatments for patients with metabolic diseases.

View Synlogic Profile